Abstract: Background　Nearly 90% of cervical intraepithelial neoplasia（CIN） and 99.7% of cervical cancer tissues have high-risk human papillomavirus （HR-HPV） infection, but there is no clear and effective treatment for persistent HR-HPV infection.Objective　To investigate the efficacy and safety of paiteling in the treatment of patients with persistent HR-HPV infection.Methods　We collected the clinical data of 123 participants who were recruited from Department of Obstetrics and Gynecology，Zhujiang Hospital of Southern Medical University from August 2015 to December 2016，including 80 with persistent HR-HPV infection and negative results of TCT（group A），15 with persistent HR-HPV infection and CIN grade 1（group B） and 28 with persistent HR-HPV infection after cervical cancer surgery and CIN grade 2-3（group C）． Paiteling treatment was given to all of them，and the response and safety were analyzed.Results　Spearman's correlation analysis showed that white blood cell count，hemoglobin，prothrombin time，thrombin time，fibrinogen，D-dimer，triacylglycerol，low density lipoprotein cholesterol and high density lipoprotein cholesterol levels increased with the progression of CIN among the patients with persistent HR-HPV infection（P<0.01）． The negative conversion rate differed significantly between groups A〔87.5% （70/80）〕，B（15/15），and C〔57.1% （16/28）〕 （P<0.001），but the cumulative negative conversion rate {group A〔91.2% （73/80）〕 vs group B（15/15） vs group C〔89.3% （25/28）〕} did not （P>0.05）． 2 cases without response were found to be infected with subtypes HR-HPV 52 and 58 by a re-examination.The follow-up revealed that among all the participants，vaginal and vulvar stinging and burning were the most common short-term adverse reactions within a 6-month treatment，and no long-term adverse reactions such as cervical adhesion，cervical erosion，as well as cervical stenosis were found during 1 to 2 years of treatment.Conclusion　Paiteling is effective and safe for the treatment of persistent HR-HPV infection.

Key words: Human papillomavirus, Paiteling, Infection, CIN, Treatment outcome

摘要： 背景　接近90%的宫颈上皮内瘤变（CIN）和99.7%的宫颈癌组织中发现有高危人乳头瘤病毒（HR-HPV）感染，但是HR-HPV持续感染目前尚无明确有效的治疗方法。目的　探究派特灵对HR-HPV持续感染患者的疗效及安全性。方法　选取2015年8月—2016年12月在南方医科大学珠江医院妇产科就诊的123例患者，依据液基薄层细胞检测（TCT）及CIN不同分级，将患者分为：A组（持续HR-HPV感染且TCT阴性，80例），B组（持续HR-HPV感染伴CINⅠ级，15例），C组（CINⅡ~Ⅲ级及宫颈癌术后HR-HPV持续感染，28例）。收集患者临床资料。并给予派特灵治疗，观察治疗效果及安全性。结果　Spearman相关分析结果显示，HR-HPV感染伴CIN不同分级与白细胞计数、血红蛋白、凝血酶原时间、凝血酶时间、纤维蛋白原、D-二聚体、三酰甘油、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇均呈正相关（P<0.01）。A、B、C组转阴率依次为87.5%（70/80）、15/15、57.1%（16/28），3组转阴率比较，差异有统计学意义（P<0.001）；A、B、C组累积转阴率依次为91.2%（73/80）、15/15、89.3%（25/28），3组累积转阴率比较，差异无统计学意义（P>0.05）。2例无效者复查亚型分别为HR-HPV 52、58。3组患者近期（用药半年内）不良反应以阴道及外阴灼刺痛最多见，远期（1~2年）随访未发现宫颈粘连、糜烂，颈口狭窄等病变。结论　派特灵对HR-HPV持续感染治疗效果较好，安全有效。

关键词: 人乳头瘤病毒, 派特灵, 感染, 宫颈上皮内瘤变, 治疗结果